Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 6/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.31 |
| ▸ | UGCG | Q16739 | 2/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026472 | 0.90 | ACKR3 (0.41) | ACKR3AHCY | |
| SCHEMBL1027928 | 0.89 | ACKR3 (0.42) | ACKR3AHCY | |
| SCHEMBL1027779 | 0.89 | ACKR3 (0.40) | ACKR3AHCY | |
| SCHEMBL1027778 | 0.89 | ACKR3 (0.43) | ACKR3AHCY | |
| SCHEMBL1028243 | 0.89 | ACKR3 (0.41) | ACKR3AHCY | |
| SCHEMBL1025930 | 0.89 | ACKR3 (0.41) | ACKR3AHCYGPR119 | |
| SCHEMBL1025983 | 0.88 | ACKR3 (0.42) | ACKR3AHCY | |
| SCHEMBL1027490 | 0.88 | ACKR3 (0.43) | ACKR3AHCY | |
| SCHEMBL1025418 | 0.87 | ACKR3 (0.41) | ACKR3AHCYGPR119 | |
| SCHEMBL1024983 | 0.87 | ACKR3 (0.41) | ACKR3AHCYPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | ACKR3 4604/4885AHCY 4/4885PRMT5 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.